Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce today that Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) have launched Rejoyn™. Rejoyn was cleared by the U.S. Food and Drug Administration (FDA) in March 2024 and is the first-and-only prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication.

Patients can obtain a prescription for Rejoyn from their current provider or from another provider via a virtual consultation from Wheel Health, Inc., whose platform can be accessed from a link on the Rejoyn website. BlinkRx is the exclusive pharmacy provider for Rejoyn and will digitally dispense access codes for Rejoyn to prescribed patients. As a digital treatment, Rejoyn can then be downloaded from mobile application stores and used at a place and time of patients' choosing. In an effort to facilitate broad access, the six-week Rejoyn treatment program is available for a limited time at a discounted price of $50 for patients. At launch, Rejoyn will be priced for payors at $200. Coverage from health insurers is expected to be forthcoming.

"We are proud to bring Rejoyn, the first-and-only FDA-cleared digital treatment for MDD symptoms, to the market," said Sanket Shah, president of Otsuka Precision Health. "Rejoyn is an important milestone on Otsuka Precision Health's journey to improving the patient experience through data-backed and digital products and services that meet patients where they are."

About Otsuka Precision Health

Combining the rigor of pharma with a data-first focus on patient experience, Otsuka Precision Health, Inc. focuses on bringing to market prescription digital therapeutics, other innovative technologies, and provides non-promotional patient support services. The company is committed to personalizing care, unlocking doors to access, and uniting a fragmented experience. OPH's current focus areas include a variety of technological interventions that help unearth personal health needs and address them as a true collaborator within the broader healthcare ecosystem.

OPH is a subsidiary of Otsuka America, Inc. (Otsuka), which is a subsidiary of Otsuka Pharmaceutical Co., Ltd. headquartered in Tokyo, Japan.